Evexta Bio Appoints Robert Doebele as CMO Consultant
July 29 2024 - 2:00AM
Business Wire
Evexta Bio SA, a clinical-stage biotechnology company focused on
developing first-in-class therapies in oncology, announces the
appointment of Robert Doebele as CMO consultant.
Dr. Doebele's extensive academic background includes a MD and
PhD in Immunology from the University of Pennsylvania School of
Medicine, residency and fellowship training in Medical Oncology and
Internal Medicine at the University of Chicago Pritzker School of
Medicine, and a Bachelor of Arts in Molecular Biology from
Princeton University.
Throughout his career, Dr. Doebele has made significant
contributions to cancer research, focusing on molecular
diagnostics, cancer biology, and the development of biomarkers. His
previous roles include Associate Clinical Professor at the
University of Colorado Anschutz Medical Campus, where he also
directed the Thoracic Oncology Research Initiative. Before joining
Evexta Bio, Robert was co-founder, Chief Scientific Officer and
Chief Medical Officer of Rain Oncology.
As CMO consultant, Robert will support the Company’s clinical
development strategy, provide expert advice for protocols,
processes and rupitasertib clinical plans and participate in
scientific advisory committees.
Scott Filosi, CEO of Evexta Bio said: “I am delighted to
welcome Robert as CMO consultant. We are confident that Robert’s
expertise will greatly enhance our ongoing efforts in advancing
clinical research and improving patient outcomes.”
About Evexta Bio
(https://www.evextabio.com)
Evexta Bio is a biopharmaceutical company exploring the new
frontiers of oncology in search of daring novel therapeutic
approaches with the potential to save lives. Now, in the clinic,
the company is currently developing two proprietary therapeutic
assets with novel mechanisms of action across several
indications:
- Rupitasertib, an optimized S6K inhibitor with efficient
AKT1/AKT3 control of compensatory AKT feed-back loop. The oral
anti-tumor agent is expected to enter phase 2 clinical trial in
ESR1mt ER+ HER2- advanced breast cancer.
- EVX020, a sole-in-class KIF20A kinesin inhibitor having shown
potent nonclinical efficacy in hematological and solid tumor
models. Two strategies are under assessment, development of EVX020
as a prodrug and as a payload for antibody-drug conjugate
(ADC).
Founded by Truffle Capital, supported by Merck KGaA (Darmstadt,
Germany) as shareholder, Evexta Bio has forged alliances with
leaders in academia and industry, including CNRS, Paoli-Calmettes
Institute (Marseille, France) and Merck KGaA. The company is
supported by seasoned management team, board of directors and
medical advisory board.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240729887134/en/
Primatice Conseil Armand Rigaudy +33 (0)7 88 96 41 84
armandrigaudy@primatice.com